N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV

Summary

To assess the safety of combination immune therapy in HIV-infected participants whose HIV is controlled with ART, by determining the incidence and severity of adverse events.

Timeline

Start

2020-01-01

Primary completion

2020-12-31

Completion

2020-12-31

Outcome

Outcome not reported

Stopped: “Contact issues”

Drugs

Indications